值得注意的是,本研究也提示,既往HER2 IHC 0被重新归类为HER2低表达的比例相对较高 (30%),这表明可以考虑对既往具有这种HER2 IHC 状态(HER2 IHC 0)的患者进行重新评估,以确定这些患者是否可以从 HER2低表达靶向治疗中受益。 其他研究...
MyPathway研究显示,曲妥珠单抗+帕妥珠单抗的双靶治疗并未使RAS突变型肠癌患者获得PFS上的益处[3]。 除了IHC、FISH检测可以用于结直肠癌HER2阳性的判读,还有研究探索了液体活检作为结直肠癌HER2阳性的判读方法。Siravegna G等使用Guardant360 cfDNA测定法测试了HERACLES A研究中29例HER2阳性患者的样本,建议血浆拷贝数(pCN...
MyPathway研究显示,曲妥珠单抗+帕妥珠单抗的双靶治疗并未使RAS突变型肠癌患者获得PFS上的益处[3]。 除了IHC、FISH检测可以用于结直肠癌HER2阳性的判读,还有研究探索了液体活检作为结直肠癌HER2阳性的判读方法。Siravegna G等使用Guardant360 cfDNA...
Purpose: The new ASCO/CAP guidelines published in 2013 (AC2013) significantly modified the scoring criteria for HER2-FISH, introducing the most controversi... Ragazzi,Bisagni,Gasparini,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2017年 Impact of 2013 ASCO/CAP guidelines on HER2 det...
the correlation between HER2 mRNA expression levels detected by APIS BCSK, and IHC HER2 scoring.Methods:A total of n=642 formalin-fixed paraffin-embedded (FFPE) BC sections, obtained by core needle biopsy or resection, underwent histological assessment observing the ASCO/CAP guidelines for IHC. Th...
Importantly, patients with IHC3+ expression had a higher ORR of 61.3% and a longer DOR of 22.1 months [171]. Currently, there are several ongoing clinical trials related to this matter (Table 2). Conclusions and perspectives HER2-targeted drugs have been effective at treating tumors for ...
HER2 status determinationinvolvesinitial assessmentof protein expression on the tumor cell membrane using IHC or possible evaluation of the number ofHER2gene copies through ISH techniques. IHC results are reportedbased on a scoring system: 0: no staining or incomplete and faint/barely perceptible membra...
由于乳腺癌和胃癌临床病理特点不同, 简单地将乳腺癌的HER2评分标准引入胃癌观察显然是不恰当的[13]. 使用乳腺癌HER2的评分标准来判断胃癌HER2表达, 将导致胃癌中阳性病例数降低[14]. 因为HER2在胃癌和乳腺癌的表达上存在两大不同点: (1)免疫组织化学(immunohistochemistry, IHC)胃癌细胞呈不完整膜着色比乳腺癌更常...
Our work has several strengths. Firstly, we rescored all of the HER2 IHC slides according to the latest standard of HER2 diagnosis by ASCO/CAP Guidelines Update [27]. On the one hand, the cut-offs for HER2-zero were downgraded since October 2013 according to the ASCO/CAP HER2 testing gu...
但与此同时,HER2检测实践中的一些问题也不断显现,例如胃镜活检标本HER2检测未得到普及;原位杂交检测率低下,并由此导致大多数免疫组织化学染色(IHC)2+的胃癌病例未能最终明确HER2状态;部分单位HER2阳性率与国内外文献报道差异较大。此外,随着全球范围内胃癌HER2研究数据以及抗HER2靶向治疗经验的积累,人们对HER2在胃癌诊疗...